CRLM in the Era of Transplant Oncology: New Hope, New Questions

Dear Colleagues,

Colorectal liver metastases (CRLM) remain one of the most challenging domains in oncologic surgery, with curative resection only available to a minority of patients. However, recent data, most notably from the TRANSMET study have brought new optimism. The demonstration of a survival benefit in selected patients with unresectable CRLM undergoing liver transplantation marks a potential paradigm shift in treatment strategy.

This emerging therapeutic avenue raises several pressing clinical and scientific questions. Should adjuvant or maintenance chemotherapy be continued post-transplant? Could liquid biopsy or circulating tumor DNA (ctDNA) be leveraged for surveillance or patient selection? What are the ethical, logistical, and immunological considerations when transplanting patients with active malignancy?

Given this rapidly evolving landscape, we propose a Special Issue dedicated to CRLM, with a focus on cutting-edge developments in transplantation, systemic therapy, molecular stratification, and post-treatment surveillance. The goal is to bring together surgical oncologists, hepatologists, transplant teams, medical oncologists, and molecular biologists to chart the future of CRLM management.

Prof. Dr. Brian Davidson
Dr. Khurum Khan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.